Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.muscletease.com
Are you over 18 and want to see adult content?
A complete backup of www.www.partyflock.nl
Are you over 18 and want to see adult content?
A complete backup of www.www.onlytorrents.com
Are you over 18 and want to see adult content?
A complete backup of www.www.smart-pays.com
Are you over 18 and want to see adult content?
A complete backup of www.www.freudenhaus.de
Are you over 18 and want to see adult content?
A complete backup of amandadouglasforcongress.com
Are you over 18 and want to see adult content?
A complete backup of www.spicystory.net
Are you over 18 and want to see adult content?
A complete backup of www.cinemagay.it
Are you over 18 and want to see adult content?
A complete backup of www.www.celebritystyleguide.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of olivermetalfurniture.in
Are you over 18 and want to see adult content?
A complete backup of travelhealthpro.org.uk
Are you over 18 and want to see adult content?
A complete backup of acbranding.azurewebsites.net
Are you over 18 and want to see adult content?
A complete backup of gregtangmath.com
Are you over 18 and want to see adult content?
A complete backup of jetblackproducts.com
Are you over 18 and want to see adult content?
A complete backup of exceltactics.com
Are you over 18 and want to see adult content?
Text
HOME - WUXI APPTEC
Our team has a proven track record developing customized programs that leverage our many years of industry-leading experience. We provide the wide range of services and guidances required to launch and maintain successful products in today’s complex regulatory environment.CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.comWUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery.HOME - WUXI APPTEC
Our team has a proven track record developing customized programs that leverage our many years of industry-leading experience. We provide the wide range of services and guidances required to launch and maintain successful products in today’s complex regulatory environment.CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.comWUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. ABOUT US | WUXI APPTEC WuXi AppTec developed from a laboratory of 7000 square feet to 30 sites worldwide. From 4 co-founders to more than 27,000 employees globally, WuXi today provides a broad portfolio of R&D and manufacturing services that support over 4,400 collaborative partnersworldwide.
CAREERS | WUXI APPTEC WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.OUR LOCATIONS
WuXi AppTec has sites all over the world. Our global approach fosters expertise in policy compliance, diverse regulatory conditions, & access to world-class services. WUXI APPTEC REPORTS RECORD FIRST-QUARTER 2021 RESULTS (SHANGHAI, April 29, 2021) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.com WUXI HEALTHCARE FORUM 2021 We are pleased to announce the WuXi Healthcare Forum 2021 will launch virtually March 15-18, 2021. This complimentary event, titled "Partnership for Patients," will bring together 6,000+ colleagues from around the world who are working to address PROSPECTUS | WUXI APPTEC WuXi AppTec’s prospectus details the company’s global offering, corporate information, industry & regulatory overviews, and financialinformation.
SOLUTIONS ARCHIVES • WUXI APPTEC LAB TESTING DIVISION We offer a true, single-platform, end-to-end solution that can be catered to your specific drug discovery and development needs – saving you money while providing industry-leading turnaround times. SMALL MOLECULE ARCHIVES • WUXI APPTEC LAB TESTING DIVISION Engaging the right partners at the right time is essential to drug developers and the success of their compound. We sat down with Grace Furman, small-molecule toxicology consultant at Paracelsus, Inc., to get her perspective on some of the most pressing challenges and NCBI ARCHIVES • WUXI APPTEC LAB TESTING DIVISION Lead optimization in the world of drug development is a multifaceted process. It is a crucial part of discovery pharmacology and toxicology, as such, is used to identify and advance the most promising drug compounds.HOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 WUXI HEALTHCARE FORUM 2021 We are pleased to announce the WuXi Healthcare Forum 2021 will launch virtually March 15-18, 2021. This complimentary event, titled "Partnership for Patients," will bring together 6,000+ colleagues from around the world who are working to addressWUXI APPTEC
ADVANTAGES. 20 years antibody development and production experience. ISO9001-2015 quality management system SGS certification. ‘one-stop’ customized antibody solutions. Strict IP protection. High quality and reasonable price. Special service for various modelorganisms. Ready to
SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.com QUALITY CERTIFICATES WuXi AppTec’s corporate commitment to quality is reflected in the quality programs/systems at its U.S. sites located in St. Paul, Minnesota; Atlanta, Georgia; and Philadelphia, Pennsylvania. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
ONCOWUXI ONCOLOGY BROWSER WE'RE SORRY BUT ONCOWUXI ONCOLOGY BROWSER DOESN'T WORK PROPERLY WITHOUT JAVASCRIPT ENABLED. PLEASE ENABLE IT TO CONTINUE. 欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码?HOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 WUXI HEALTHCARE FORUM 2021 We are pleased to announce the WuXi Healthcare Forum 2021 will launch virtually March 15-18, 2021. This complimentary event, titled "Partnership for Patients," will bring together 6,000+ colleagues from around the world who are working to addressWUXI APPTEC
ADVANTAGES. 20 years antibody development and production experience. ISO9001-2015 quality management system SGS certification. ‘one-stop’ customized antibody solutions. Strict IP protection. High quality and reasonable price. Special service for various modelorganisms. Ready to
SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.com QUALITY CERTIFICATES WuXi AppTec’s corporate commitment to quality is reflected in the quality programs/systems at its U.S. sites located in St. Paul, Minnesota; Atlanta, Georgia; and Philadelphia, Pennsylvania. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
ONCOWUXI ONCOLOGY BROWSER WE'RE SORRY BUT ONCOWUXI ONCOLOGY BROWSER DOESN'T WORK PROPERLY WITHOUT JAVASCRIPT ENABLED. PLEASE ENABLE IT TO CONTINUE. 欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码? ABOUT US | WUXI APPTEC About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theOUR LOCATIONS
WuXi ATU. Cell therapy products, gene carrier research and development, production and other related services business. A area 1719-6, Huishan Avenue, Huishan Economic Development Zone, Wuxi, Jiangsu, China. +86 (510) 8858-3666. WUXI APPTEC REPORTS RECORD FIRST-QUARTER 2021 RESULTS (SHANGHAI, April 29, 2021) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter WUXI APPTEC COMPLETES ACQUISITION OF OXGENE TO FURTHER PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.com WUXI HEALTHCARE FORUM 2021 We are pleased to announce the WuXi Healthcare Forum 2021 will launch virtually March 15-18, 2021. This complimentary event, titled "Partnership for Patients," will bring together 6,000+ colleagues from around the world who are working to address FINANCIAL REPORTS AND PRESENTATIONS WuXi AppTec publishes quarterly financial reports, a financial Annual Report, and interim reports. GENERAL TOXICOLOGY • WUXI APPTEC LAB TESTING DIVISION Scientific Services. Preclinical toxicology assessment is required by regulatory authorities to establish the toxicological profiles of your new drug candidate prior to First-in-Human (FIH) studies. We can accommodate your GLP studies of varying size, length, complexity and overall regulatory compliance. Your studies will be conducted in our A GUIDE TO ISO 10993-18'S ANALYTICAL EVALUATION THRESHOLD A Guide to ISO 10993-18’s Analytical Evaluation Threshold. New identification standards are putting pressure on manufacturers’ submissions. Make sure your sensitivity is up to regulations. Medical Device Regulation (MDR) and recent International Organization for Standardization (ISO) revisions emphasize the importance of chemical CLICK IS PIONEERING AND DEVELOPING CUTTING-EDGE DIGITAL What is digital health? In broad terms, it is the convergence of digital technologies with medicine, health and society to boost treatment efficacy and ABOUT US | WUXI APPTECOUR LEADERSHIPWUXI LAB TESTINGMEDIA CENTERCONTACT USOUR LOCATIONSOUR CULTURE About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theHOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.comWUXI APPTEC
Head of HitS. 14+ yrs experience on Med-Chem at WuXi AppTec. Experienced in chemistry and drug discovery. Letian Kuai Ph.D. Exec. Dir. Head of Strategy & Technology CSO of Crelux. 10+ yrs experience on DEL at GSK. Experienced in biology, informatics and drug discovery.Gundel Hager, Ph.D.
HOME • WUXI APPTEC LAB TESTING DIVISION WuXi AppTec’s Laboratory Testing Division is a comprehensive integrated testing platform supporting customers across the full spectrum of their development efforts to deliver innovative medicines to patients. We are passionately committed to our role in enhancing the quality of human lives. We are a unique, world-class, globallyintegrated
WUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码? ABOUT US | WUXI APPTECOUR LEADERSHIPWUXI LAB TESTINGMEDIA CENTERCONTACT USOUR LOCATIONSOUR CULTURE About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theHOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.comWUXI APPTEC
Head of HitS. 14+ yrs experience on Med-Chem at WuXi AppTec. Experienced in chemistry and drug discovery. Letian Kuai Ph.D. Exec. Dir. Head of Strategy & Technology CSO of Crelux. 10+ yrs experience on DEL at GSK. Experienced in biology, informatics and drug discovery.Gundel Hager, Ph.D.
HOME • WUXI APPTEC LAB TESTING DIVISION WuXi AppTec’s Laboratory Testing Division is a comprehensive integrated testing platform supporting customers across the full spectrum of their development efforts to deliver innovative medicines to patients. We are passionately committed to our role in enhancing the quality of human lives. We are a unique, world-class, globallyintegrated
WUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码?OUR LOCATIONS
WuXi ATU. Cell therapy products, gene carrier research and development, production and other related services business. A area 1719-6, Huishan Avenue, Huishan Economic Development Zone, Wuxi, Jiangsu, China. +86 (510) 8858-3666. CAREERS | WUXI APPTEC Overview. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theANNOUNCEMENTS
Investor-related announcements include information relevant to shareholders or those interested in buying stock in WuXi AppTec.WUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. HOME • WUXI APPTEC LAB TESTING DIVISION WuXi AppTec’s Laboratory Testing Division is a comprehensive integrated testing platform supporting customers across the full spectrum of their development efforts to deliver innovative medicines to patients. We are passionately committed to our role in enhancing the quality of human lives. We are a unique, world-class, globallyintegrated
WUXI APPTEC
WuXi AppTec HitS will provide a DELight kit containing DEL, affinity matrix and buffers, and a step-by-step experiment manual. Drug developers perform affinity selection according to the manual and return the sample to WuXi AppTec HitS upon completion. WuXi AppTec HitS is responsible for analysis such as PCR amplification, qPCRdetermination
TESTING • WUXI APPTEC MEDICAL DEVICE TESTING We offer a broad range of preclinical safety and regulatory compliance testing to the highest international quality standards, making us the foremost choice for long-lasting partnerships with medical device manufacturers around the world. WuXi AppTec Medical Device Testing offers services in St. Paul, MN, Atlanta, GA, and Suzhou, China. ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. WHAT TO ASK BEFORE SUBMITTING YOUR MEDICAL DEVICE FOR APPROVAL Testing your medical device properly and preparing a strong regulatory submission is a dynamic yet crucial part of bringing the product tothe market.
ONCOWUXI ONCOLOGY BROWSER WE'RE SORRY BUT ONCOWUXI ONCOLOGY BROWSER DOESN'T WORK PROPERLY WITHOUT JAVASCRIPT ENABLED. PLEASE ENABLE IT TO CONTINUE. ABOUT US | WUXI APPTECOUR LEADERSHIPWUXI LAB TESTINGMEDIA CENTERCONTACT USOUR LOCATIONSOUR CULTURE About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theHOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.comWUXI APPTEC
Head of HitS. 14+ yrs experience on Med-Chem at WuXi AppTec. Experienced in chemistry and drug discovery. Letian Kuai Ph.D. Exec. Dir. Head of Strategy & Technology CSO of Crelux. 10+ yrs experience on DEL at GSK. Experienced in biology, informatics and drug discovery.Gundel Hager, Ph.D.
WUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码? ABOUT US | WUXI APPTECOUR LEADERSHIPWUXI LAB TESTINGMEDIA CENTERCONTACT USOUR LOCATIONSOUR CULTURE About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theHOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.comWUXI APPTEC
Head of HitS. 14+ yrs experience on Med-Chem at WuXi AppTec. Experienced in chemistry and drug discovery. Letian Kuai Ph.D. Exec. Dir. Head of Strategy & Technology CSO of Crelux. 10+ yrs experience on DEL at GSK. Experienced in biology, informatics and drug discovery.Gundel Hager, Ph.D.
WUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码?OUR LOCATIONS
WuXi ATU. Cell therapy products, gene carrier research and development, production and other related services business. A area 1719-6, Huishan Avenue, Huishan Economic Development Zone, Wuxi, Jiangsu, China. +86 (510) 8858-3666. CAREERS | WUXI APPTEC Overview. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theANNOUNCEMENTS
Investor-related announcements include information relevant to shareholders or those interested in buying stock in WuXi AppTec. HOME • WUXI APPTEC LAB TESTING DIVISION WuXi AppTec’s Laboratory Testing Division is a comprehensive integrated testing platform supporting customers across the full spectrum of their development efforts to deliver innovative medicines to patients. We are passionately committed to our role in enhancing the quality of human lives. We are a unique, world-class, globallyintegrated
TESTING • WUXI APPTEC MEDICAL DEVICE TESTING We offer a broad range of preclinical safety and regulatory compliance testing to the highest international quality standards, making us the foremost choice for long-lasting partnerships with medical device manufacturers around the world. WuXi AppTec Medical Device Testing offers services in St. Paul, MN, Atlanta, GA, and Suzhou, China. WHAT TO ASK BEFORE SUBMITTING YOUR MEDICAL DEVICE FOR APPROVAL Testing your medical device properly and preparing a strong regulatory submission is a dynamic yet crucial part of bringing the product tothe market.
WUXI APPTEC
WuXi AppTec HitS will provide a DELight kit containing DEL, affinity matrix and buffers, and a step-by-step experiment manual. Drug developers perform affinity selection according to the manual and return the sample to WuXi AppTec HitS upon completion. WuXi AppTec HitS is responsible for analysis such as PCR amplification, qPCRdetermination
ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. QUALITY CERTIFICATES WuXi AppTec’s corporate commitment to quality is reflected in the quality programs/systems at its U.S. sites located in St. Paul, Minnesota; Atlanta, Georgia; and Philadelphia, Pennsylvania. ONCOWUXI ONCOLOGY BROWSER We're sorry but OncoWuXi Oncology Browser doesn't work properly without JavaScript enabled. Please enable it to continue.HOME - WUXI APPTEC
Our team has a proven track record developing customized programs that leverage our many years of industry-leading experience. We provide the wide range of services and guidances required to launch and maintain successful products in today’s complex regulatory environment. WUXI APPTEC REPORTS RECORD FIRST-QUARTER 2021 RESULTS (SHANGHAI, April 29, 2021) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-QuarterCUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password WUXI ADVANCED THERAPIES EXPANDS PHILADELPHIA CAMPUS WITH November 18, 2020 - Philadelphia, PA - WuXi Advanced Therapies Inc. (WuXi ATU) – a business unit of WuXi AppTec offering end-to-end contract services for the cell and gene therapies industry – today announced the completion of a facility expansion that will triple its advanced testing capacity at the company’s Philadelphia Navy Yardcampus.
首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 WUXI HEALTHCARE FORUM 2021 We are pleased to announce the WuXi Healthcare Forum 2021 will launch virtually March 15-18, 2021. This complimentary event, titled "Partnership for Patients," will bring together 6,000+ colleagues from around the world who are working to address SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.com QUALITY CERTIFICATES WuXi AppTec’s corporate commitment to quality is reflected in the quality programs/systems at its U.S. sites located in St. Paul, Minnesota; Atlanta, Georgia; and Philadelphia, Pennsylvania. ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. 欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码?HOME - WUXI APPTEC
Our team has a proven track record developing customized programs that leverage our many years of industry-leading experience. We provide the wide range of services and guidances required to launch and maintain successful products in today’s complex regulatory environment. WUXI APPTEC REPORTS RECORD FIRST-QUARTER 2021 RESULTS (SHANGHAI, April 29, 2021) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-QuarterCUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password WUXI ADVANCED THERAPIES EXPANDS PHILADELPHIA CAMPUS WITH November 18, 2020 - Philadelphia, PA - WuXi Advanced Therapies Inc. (WuXi ATU) – a business unit of WuXi AppTec offering end-to-end contract services for the cell and gene therapies industry – today announced the completion of a facility expansion that will triple its advanced testing capacity at the company’s Philadelphia Navy Yardcampus.
首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 WUXI HEALTHCARE FORUM 2021 We are pleased to announce the WuXi Healthcare Forum 2021 will launch virtually March 15-18, 2021. This complimentary event, titled "Partnership for Patients," will bring together 6,000+ colleagues from around the world who are working to address SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.com QUALITY CERTIFICATES WuXi AppTec’s corporate commitment to quality is reflected in the quality programs/systems at its U.S. sites located in St. Paul, Minnesota; Atlanta, Georgia; and Philadelphia, Pennsylvania. ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. 欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码?OUR LOCATIONS
WuXi AppTec has sites all over the world. Our global approach fosters expertise in policy compliance, diverse regulatory conditions, & access to world-class services. CAREERS | WUXI APPTEC WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. WUXI APPTEC REPORTS RECORD FIRST-QUARTER 2021 RESULTS (SHANGHAI, April 29, 2021) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter WUXI APPTEC COMPLETES ACQUISITION OF OXGENE TO FURTHER PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalableANNOUNCEMENTS
Investor-related announcements include information relevant to shareholders or those interested in buying stock in WuXi AppTec. SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.com FINANCIAL REPORTS AND PRESENTATIONS WuXi AppTec publishes quarterly financial reports, a financial Annual Report, and interim reports. WHAT TO ASK BEFORE SUBMITTING YOUR MEDICAL DEVICE FOR APPROVAL Testing your medical device properly and preparing a strong regulatory submission is a dynamic yet crucial part of bringing the product tothe market.
QUALITY CERTIFICATES WuXi AppTec’s corporate commitment to quality is reflected in the quality programs/systems at its U.S. sites located in St. Paul, Minnesota; Atlanta, Georgia; and Philadelphia, Pennsylvania. ONCOWUXI ONCOLOGY BROWSER We're sorry but OncoWuXi Oncology Browser doesn't work properly without JavaScript enabled. Please enable it to continue. ABOUT US | WUXI APPTECOUR LEADERSHIPWUXI LAB TESTINGMEDIA CENTERCONTACT USOUR LOCATIONSOUR CULTURE About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theHOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.comWUXI APPTEC
Head of HitS. 14+ yrs experience on Med-Chem at WuXi AppTec. Experienced in chemistry and drug discovery. Letian Kuai Ph.D. Exec. Dir. Head of Strategy & Technology CSO of Crelux. 10+ yrs experience on DEL at GSK. Experienced in biology, informatics and drug discovery.Gundel Hager, Ph.D.
WUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码? ABOUT US | WUXI APPTECOUR LEADERSHIPWUXI LAB TESTINGMEDIA CENTERCONTACT USOUR LOCATIONSOUR CULTURE About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theHOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.comWUXI APPTEC
Head of HitS. 14+ yrs experience on Med-Chem at WuXi AppTec. Experienced in chemistry and drug discovery. Letian Kuai Ph.D. Exec. Dir. Head of Strategy & Technology CSO of Crelux. 10+ yrs experience on DEL at GSK. Experienced in biology, informatics and drug discovery.Gundel Hager, Ph.D.
WUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码?OUR LOCATIONS
WuXi ATU. Cell therapy products, gene carrier research and development, production and other related services business. A area 1719-6, Huishan Avenue, Huishan Economic Development Zone, Wuxi, Jiangsu, China. +86 (510) 8858-3666. CAREERS | WUXI APPTEC Overview. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theANNOUNCEMENTS
Investor-related announcements include information relevant to shareholders or those interested in buying stock in WuXi AppTec. HOME • WUXI APPTEC LAB TESTING DIVISION WuXi AppTec’s Laboratory Testing Division is a comprehensive integrated testing platform supporting customers across the full spectrum of their development efforts to deliver innovative medicines to patients. We are passionately committed to our role in enhancing the quality of human lives. We are a unique, world-class, globallyintegrated
TESTING • WUXI APPTEC MEDICAL DEVICE TESTING We offer a broad range of preclinical safety and regulatory compliance testing to the highest international quality standards, making us the foremost choice for long-lasting partnerships with medical device manufacturers around the world. WuXi AppTec Medical Device Testing offers services in St. Paul, MN, Atlanta, GA, and Suzhou, China. WHAT TO ASK BEFORE SUBMITTING YOUR MEDICAL DEVICE FOR APPROVAL Testing your medical device properly and preparing a strong regulatory submission is a dynamic yet crucial part of bringing the product tothe market.
WUXI APPTEC
WuXi AppTec HitS will provide a DELight kit containing DEL, affinity matrix and buffers, and a step-by-step experiment manual. Drug developers perform affinity selection according to the manual and return the sample to WuXi AppTec HitS upon completion. WuXi AppTec HitS is responsible for analysis such as PCR amplification, qPCRdetermination
ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. QUALITY CERTIFICATES WuXi AppTec’s corporate commitment to quality is reflected in the quality programs/systems at its U.S. sites located in St. Paul, Minnesota; Atlanta, Georgia; and Philadelphia, Pennsylvania. ONCOWUXI ONCOLOGY BROWSER We're sorry but OncoWuXi Oncology Browser doesn't work properly without JavaScript enabled. Please enable it to continue. ABOUT US | WUXI APPTECOUR LEADERSHIPWUXI LAB TESTINGMEDIA CENTERCONTACT USOUR LOCATIONSOUR CULTURE About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theHOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.comWUXI APPTEC
Head of HitS. 14+ yrs experience on Med-Chem at WuXi AppTec. Experienced in chemistry and drug discovery. Letian Kuai Ph.D. Exec. Dir. Head of Strategy & Technology CSO of Crelux. 10+ yrs experience on DEL at GSK. Experienced in biology, informatics and drug discovery.Gundel Hager, Ph.D.
WUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码? ABOUT US | WUXI APPTECOUR LEADERSHIPWUXI LAB TESTINGMEDIA CENTERCONTACT USOUR LOCATIONSOUR CULTURE About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theHOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
CUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. Password 首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.comWUXI APPTEC
Head of HitS. 14+ yrs experience on Med-Chem at WuXi AppTec. Experienced in chemistry and drug discovery. Letian Kuai Ph.D. Exec. Dir. Head of Strategy & Technology CSO of Crelux. 10+ yrs experience on DEL at GSK. Experienced in biology, informatics and drug discovery.Gundel Hager, Ph.D.
WUXI APPTEC
WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码?OUR LOCATIONS
WuXi ATU. Cell therapy products, gene carrier research and development, production and other related services business. A area 1719-6, Huishan Avenue, Huishan Economic Development Zone, Wuxi, Jiangsu, China. +86 (510) 8858-3666. CAREERS | WUXI APPTEC Overview. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theANNOUNCEMENTS
Investor-related announcements include information relevant to shareholders or those interested in buying stock in WuXi AppTec. HOME • WUXI APPTEC LAB TESTING DIVISION WuXi AppTec’s Laboratory Testing Division is a comprehensive integrated testing platform supporting customers across the full spectrum of their development efforts to deliver innovative medicines to patients. We are passionately committed to our role in enhancing the quality of human lives. We are a unique, world-class, globallyintegrated
TESTING • WUXI APPTEC MEDICAL DEVICE TESTING We offer a broad range of preclinical safety and regulatory compliance testing to the highest international quality standards, making us the foremost choice for long-lasting partnerships with medical device manufacturers around the world. WuXi AppTec Medical Device Testing offers services in St. Paul, MN, Atlanta, GA, and Suzhou, China. WHAT TO ASK BEFORE SUBMITTING YOUR MEDICAL DEVICE FOR APPROVAL Testing your medical device properly and preparing a strong regulatory submission is a dynamic yet crucial part of bringing the product tothe market.
WUXI APPTEC
WuXi AppTec HitS will provide a DELight kit containing DEL, affinity matrix and buffers, and a step-by-step experiment manual. Drug developers perform affinity selection according to the manual and return the sample to WuXi AppTec HitS upon completion. WuXi AppTec HitS is responsible for analysis such as PCR amplification, qPCRdetermination
ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. QUALITY CERTIFICATES WuXi AppTec’s corporate commitment to quality is reflected in the quality programs/systems at its U.S. sites located in St. Paul, Minnesota; Atlanta, Georgia; and Philadelphia, Pennsylvania. ONCOWUXI ONCOLOGY BROWSER We're sorry but OncoWuXi Oncology Browser doesn't work properly without JavaScript enabled. Please enable it to continue. ABOUT US | WUXI APPTECOUR LEADERSHIPWUXI LAB TESTINGMEDIA CENTERCONTACT USOUR LOCATIONSOUR CULTURE About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theOUR LOCATIONS
WuXi ATU. Cell therapy products, gene carrier research and development, production and other related services business. A area 1719-6, Huishan Avenue, Huishan Economic Development Zone, Wuxi, Jiangsu, China. +86 (510) 8858-3666. CAREERS | WUXI APPTEC Overview. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theHOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTECWUXI APPTEC CLIENT PORTALWUXI APPTEC INCWUXI APPTEC INTRANETAPPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.com ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码?LOADING...
Loading Loading
ABOUT US | WUXI APPTECOUR LEADERSHIPWUXI LAB TESTINGMEDIA CENTERCONTACT USOUR LOCATIONSOUR CULTURE About Us. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theOUR LOCATIONS
WuXi ATU. Cell therapy products, gene carrier research and development, production and other related services business. A area 1719-6, Huishan Avenue, Huishan Economic Development Zone, Wuxi, Jiangsu, China. +86 (510) 8858-3666. CAREERS | WUXI APPTEC Overview. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theHOME - WUXI APPTEC
Understanding the chemical constituents in your product, delivery system, container or disposable manufacturing components is important to understand and leverage to support safety. Our extractables and leachables program was designed with toxicological safety assessment in mind. And, you can’t do that with a chemistry report full ofunknowns.
首页 | 药明康德 药明康德2021年第一季度增速创新高. 上海,2021年04月29日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.sh / 2359.hk)发布2021年第一季度报告。 SIGN IN - WUXI APPTECWUXI APPTEC CLIENT PORTALWUXI APPTEC INCWUXI APPTEC INTRANETAPPTEC Please login with either method: Domain account: pharmatechs\\yao_xiaoming. Email account: yao_xiaoming@wuxiapptec.com ORDERING - WUXI APPTEC WuXi Ordering System (WOS) Please begin using the WuXi Ordering System (WOS) as it is a new interactive, online ordering form for test articles being submitted to our St. Paul and Atlanta facilities. 上海药明津石医药科技有限公司 上海药明津石医药科技有限公司(“药明津石”)是一家专业提供临床试验相关服务的smo公司,成立于2009年,总部位于上海,在全国各地设有近20个办公室,是上海药明康德新药开发有限公司的全资子公司。截至目前,津石医药在全国120+个城市拥有一支超过2000名crc的稳定的专业临床研究团队,在
欢迎来到药明津石临床研究管理学院TRANSLATE THIS PAGE 欢迎来到药明津石临床研究管理学院 忘记密码?LOADING...
Loading Loading
CAREERS | WUXI APPTEC Overview. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the WUXI NEWS | WUXI APPTEC 2021/04/29. WuXi AppTec Reports Record First-Quarter 2021 Results (SHANGHAI, April 29, 2021) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments toCUSTOMER LOGIN
Registered Customers Terms and Conditions. Email. PasswordANNOUNCEMENTS
Investor-related announcements include information relevant to shareholders or those interested in buying stock in WuXi AppTec. WUXI ADVANCED THERAPIES EXPANDS PHILADELPHIA CAMPUS WITH November 18, 2020 - Philadelphia, PA - WuXi Advanced Therapies Inc. (WuXi ATU) – a business unit of WuXi AppTec offering end-to-end contract services for the cell and gene therapies industry – today announced the completion of a facility expansion that will triple its advanced testing capacity at the company’s Philadelphia Navy Yardcampus.
WUXI APPTEC
Head of HitS. 14+ yrs experience on Med-Chem at WuXi AppTec. Experienced in chemistry and drug discovery. Letian Kuai Ph.D. Exec. Dir. Head of Strategy & Technology CSO of Crelux. 10+ yrs experience on DEL at GSK. Experienced in biology, informatics and drug discovery.Gundel Hager, Ph.D.
WHAT TO ASK BEFORE SUBMITTING YOUR MEDICAL DEVICE FOR APPROVAL Testing your medical device properly and preparing a strong regulatory submission is a dynamic yet crucial part of bringing the product tothe market.
TESTING • WUXI APPTEC MEDICAL DEVICE TESTING We offer a broad range of preclinical safety and regulatory compliance testing to the highest international quality standards, making us the foremost choice for long-lasting partnerships with medical device manufacturers around the world. WuXi AppTec Medical Device Testing offers services in St. Paul, MN, Atlanta, GA, and Suzhou, China. ONCOWUXI ONCOLOGY BROWSER We're sorry but OncoWuXi Oncology Browser doesn't work properly without JavaScript enabled. Please enable it to continue.LOADING...
Loading Loading
联系我们 EN 简 繁关于我们
服务
公司平台
新闻
加入我们
投资者关系
药明康德
创建赋能平台
承载医药梦想
研发 创新 平台 变革 精准 未来我们的愿景
成为全球医药健康产业 最高、最宽和最深的能力和技术平台, 让天下没有难做的药,难治的病 我们的核心价值观 诚实敬业 共苦共享 做对的事 把事做好关于我们
平台驱动
服务世界
药明康德成立于2000年12月,为全球生物医药行业提供全方位、一体化的新药研发和生产服务。通过赋能全球制药、生物科技和医疗器械公司,药明康德致力于推动新药研发进程,为患者带来突破性的诊疗方案。服务范围涵盖化学药研发和生产、细胞及基因疗法研发生产、医疗器械测试等领域。目前,药明康德的赋能平台正承载着来自全球30多个国家的3600多家合作伙伴的研发创新项目,致力于将更多新药、好药带给全球病患,早日实现“让天下没有难做的药,难治的病”的梦想。查看更多
服务与解决方案 开放式能力与技术平台 承载着来自全球 30 多个国家的 3600 多家创新合作伙伴的数千个研发项目化学药研发
和生产
细胞及基因疗法研发生产
药物研发和医疗器械测试
临床试验服务
化学药研发
和生产
公司平台
平台驱动 服务世界 成为全球医药健康产业最高、最宽和最深的能力和技术平台研究服务部
提供全面的端到端 药物发现解决方案查看更多__
测试事业部
为药物开发和医疗设备创新提供 世界级、全球一体化的检测解决方案查看更多__
合全药业
全球领先的医药开发和生产平台
查看更多__
高端治疗部
细胞疗法和基因疗法研发生产平台
查看更多__
康德弘翼
提供全面的全球临床发展解决方案, 在60多个国家提供专用资源查看更多__
津石医药
临床试验现场操作 I-IV期药物 和医疗器械研究查看更多__
览博网
连接研发产品、供应商和买家 的全球电子商务平台查看更多__
新闻
了解药明康德最新资讯 药明康德推出DNA编码化合物库服务包DELight,加速早期新药发现进程 药明康德2019年中报收入和经调整净利润实现加速增长 生基医药与锦斯生物合作开拓用于先进治疗技术的病毒载体研发生产服务 合全药业上海分析服务部及常州基地零缺陷通过美国FDA现场检查 药明康德测试事业部祝贺博芮健公司用于治疗阿尔茨海默病的创新药通过FDA临床试验许可 药明康德入选《麻省理工科技评论》“50家聪明的公司”榜单 药明康德推出DNA编码化合物库服务包DELIGHT,加速早期新药发现进程 中国上海,美国波士顿,2019年9月4日 - 药明康德今日宣布推出DNA编码化合物库服务包DELight,通过领先的DNA编码化合物库技术(DNA Encoded-Library,简称DEL)为全球客户提供更具性价比、更高效的苗头化合物筛选服务,从而加速新药发现进程,推动新药、好药早日上市,造福全球病患。阅读更多
药明康德2019年中报收入和经调整净利润实现加速增长 上海,2019年8月19日,今日,为全球生物医药行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司(股份代码:603259.SH/
2359.HK)发布2019年中期报告。通过赋能全球制药、生物科技和医疗器械公司,药明康德致力于推动新药研发进程,为患者带来突破性的诊疗方案。阅读更多
生基医药与锦斯生物合作开拓用于先进治疗技术的病毒载体研发生产服务 中国上海,2019年8月13日 - 药明康德全资子公司无锡生基医药科技有限公司(“生基医药”)和上海锦斯生物技术有限公司(“锦斯生物”)近日签署战略合作协议,宣布将共同开拓用于先进治疗技术的病毒载体工业化领域,为客户提供包括溶瘤病毒在内的多种可复制生产型基因治疗病毒载体研发生产服务。此次合作将进一步提升药明康德基因治疗研发生产平台能力,更好地为客户提供覆盖全产业链的基因治疗产品的研发生产服务,推动更多创新疗法早日进入市场,造福全球病患。阅读更多
合全药业上海分析服务部及常州基地零缺陷通过美国FDA现场检查 中国上海,2019年7月23日——药明康德子公司合全药业宣布其位于上海的分析服务部和常州的原料药研发及生产基地在同一周内均以零缺陷的结果顺利通过美国FDA的现场检查。这不仅标志着合全药业的质量体系可以常态化接受全球监管机构的检查,也再次印证了合全药业领先的新药研发和生产一体化平台,能够为全球客户提供符合国际最高质量监管标准的服务,助力更多新药、好药早日进入市场,造福病患。阅读更多
药明康德测试事业部祝贺博芮健公司用于治疗阿尔茨海默病的创新药通过FDA临床试验许可 上海,2019年7月8日——近日,药明康德合作伙伴上海博芮健制药有限公司(简称:博芮健)迎来重磅喜讯,其用于治疗阿尔茨海默病(AD)的小分子新药BrAD-R13,已顺利通过美国FDA临床试验默示许可。药明康德测试事业部联合多个业务部门为博芮健提供了从药物合成到注册申报的全方位、一体化研发服务,更是首次帮助客户以电子申报(eCTD)形式完成了美国FDA的新药临床试验(IND)申请。这标志着药明康德的新药研发及全球申报一体化(WIND)服务平台,能够为全球客户提供符合中国国家药品监督管理局(NMPA)和美国FDA标准的中美双报服务,助力客户加速新药上市进程,造福全球病患。阅读更多
药明康德入选《麻省理工科技评论》“50家聪明的公司”榜单 上海,2019年6月29日——今日,国际权威科技媒体《麻省理工科技评论》(MIT Technology Review)公布了2019年“50家聪明的公司”(TR 50)评选结果。药明康德通过其独特的开放式医药研发赋能平台,帮助全球客户加快新药研发进程,因此成功入选该权威榜单。阅读更多
加入我们
欢迎加入
我们的团队
成为创造美好生活的一部分加入我们
投资者关系
最新的财务报告、公告和资源查看更多
联系我们
药明康德总部
中国上海外高桥自贸区富特中路288号邮编:200131
电话:+86 (21) 5046-1111 (总机) 传真:+86 (21) 5046-1000 业务咨询和客户服务 电话:400-820-0985(中国大陆) +86 (21) 2066-3734(全球) 邮箱:wuxiconcierge@wuxiapptec.com官方微信
领英
查看更多__
2019 WuXi
AppTec使用条款 | 隐私声明 | 沪ICP备10016157号 | 沪公网安备31011502009444号2019 WuXi AppTec
使用条款 | 隐私声明 | 沪ICP备10016157号 沪公网安备31011502009444号Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0